CD38 Antibody High-Affinity Binding Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD38 antibodies have limited recognition activity, cytotoxic activity, and tumor inhibition capabilities, necessitating the development of a new antibody with enhanced affinity and specificity to effectively target and kill CD38+ tumor cells.
Innovation Solution
A CD38 antibody with a KD value of 1×10-9M or below that binds specifically to CD38 protein, utilizing antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis to kill and inhibit tumor growth, while avoiding binding to unrelated antigens like BSA, CD19, TROP2, CD47, AXL, and Gas6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently developed CD38 antibodies are used, then they can bind to CD38 protein and exhibit some cytotoxic activity, but they have limited recognition activity, limited cytotoxic activity, and limited ability in inhibiting tumors
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding affinity parameters. The new CD38 antibody achieves a KD value of 1×10^-9 M or below, representing a significant improvement in binding strength compared to existing antibodies. This parameter optimization directly enhances both recognition activity and tumor inhibition capability simultaneously
Solution Approach 2:
The patent employs composite material principles by creating an antibody with enhanced structural properties. The antibody is designed with specific amino acid sequences and structural configurations that combine multiple functional characteristics: high affinity binding, ADCC activity, and tumor cell killing capability, resulting in a composite functional entity that overcomes the limitations of existing single-function antibodies
2Object-generated harmful factors
If currently developed CD38 antibodies are used, then they can kill CD38+ cells by ADCC and CDC, but they have limited cytotoxic activity
Solution Approach 1:
The patent optimizes cytotoxic activity parameters by engineering the antibody to achieve KD value of 1×10^-9 M or below, which enhances the stability and effectiveness of ADCC and CDC mechanisms. This parameter improvement directly translates to increased killing efficiency of CD38+ tumor cells
3Productivity
If currently developed CD38 antibodies are used, then they can inhibit tumor growth, but they have limited ability in inhibiting tumors
Solution Approach 1:
The patent applies parameter changes by achieving a KD value of 1×10^-9 M or below, which represents enhanced binding affinity. This improved binding parameter directly correlates with increased tumor inhibition capability, allowing the antibody to effectively target and inhibit CD38+ tumor cells including multiple myeloma, lymphoma, and leukemia cells
4Reliability
If a new CD38 antibody is developed with higher affinity, then it can bind to CD38 protein with higher affinity and specificity, but the development complexity increases
Solution Approach 1:
The patent achieves high binding affinity (KD ≤ 1×10^-9 M) through systematic parameter optimization of the antibody structure. By focusing on key binding parameters and using rational design approaches, the development process manages complexity while achieving superior affinity and specificity for CD38 protein
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively kills and damages CD38+ tumor cells, inhibits tumor growth, and shows specificity to CD38 protein, outperforming existing antibodies in binding affinity and tumor inhibition, particularly in multiple myeloma, lymphoma, and leukemia cells.
Implementation Method 1
it may bind to the CD38 protein with a higher affinity and specificity; it may inhibit the binding of a CD38 protein to CD38 ligand
Implementation Method 2
it may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC)
Implementation Method 3
it may kill CD38+ cells by means of complement-dependent cytotoxicity (CDC)
Implementation Method 4
it may kill CD38+ cells by means of apoptosis
Data Source
AI summary
Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.